Navigation Links
EAU Research Foundation organizes meeting in Amsterdam highlighting translational research results
Date:4/29/2009

On 22 and 23 June 2009, the Prostate Cancer Translational Research in Europe (PCTRE) meeting will be held in the Beurs van Berlage in Amsterdam (NL). Translational research transforms scientific discoveries arising from laboratory, clinical or population studies into clinical applications to reduce cancer incidence, morbidity and mortality.

The European Association of Urology (EAU) provides an excellent forum to disseminate knowledge in specialised meetings. Therefore, the EAU Research Foundation has taken the initiative for this meeting.

The focus is on prostate cancer, the most common male malignancy in most European countries with 346,000 new cases diagnosed each year in Europe. Research efforts have increased steadily over the past two decades. "However the funding of cancer in research is very competitive", says Jack Schalken, Nijmegen Medical Centre (NL). It is, therefore, of particular importance that within the European Union based framework programme many prostate cancer consortia were funded in the last 5 years totaling approximately 40 million. "The translation of our understanding of prostate cancer development and progression to the bedside of the patient plays a pivotal role", Schalken, coordinator of PRIMA, one of the consortia, says. "Thus it is time to present the highlights of these efforts during this unique meeting".

Marion Bussemakers, EU project advisor at the Nijmegen Medical Centre, adds: "The European Union is keen to show the European public what is done with the money spent on prostate cancer research and to discuss the future of urologic research. Therefore Ms Maria Vidal, Scientific Officer, DG Research, European Commission, will be joining the meeting."

How will diagnostics and therapy of prostate cancer change in future? Diagnostics has already changed with the PCA3 marker. Final results from the European Randomised Study of Screening for Prostate Cancer, recently unveiled at the 24th Annual EAU Congress in Stockholm (SE), show that prostate cancer screening reduces deaths by 20 per cent. And there is more to come. "The Prima consortium," according to Prof. Jack Schalken, "has yielded three new lead compounds for the treatment of prostate cancer." These new compounds will be introduced in Amsterdam.

Top speakers will be recruited from 8 European Union framework programmes. Researchers, EU officials and representatives of the patient advocacy groups are invited to join the meeting. Furthermore, US based scientists will join to see how 'across the pond' collaboration can be improved. The faculty includes world-reknowned urologists such as Anders Bjartell, Freddie Hamdy, Peter Mulders and Per-Anders Abrahamsson.

The programme includes, among other things, the following highlights: Molecular genetics of prostate cancer, From molecular target to clinical molecular diagnostics, Targeted therapies and a round table discussion on 'Biomarkers in prostate cancer, where do we go?'

A press conference will be organised on Monday 22 June at 17:00 hours. Registration is free for media representatives.

For more information and registration, please visit http://pctre2009.uroweb.org


'/>"/>

Contact: Lindy Brouwer
l.brouwer@uroweb.org
European Association of Urology
Source:Eurekalert

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. Children of depressed moms do better when dad is involved, SLU researcher finds
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
5. New research shows how chronic stress worsens neurodegenerative disease course
6. New research explores newborn in-hospital weight loss
7. Research may unlock mystery of autisms origin in the brain
8. Bipolar disorder relapses halved by Melbourne researchers
9. HIVs impact in Zimbabwe explored in new research
10. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
11. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , ... March 28, 2017 , ... ... plans work, the Self-Funding Success website has recently developed and published an informational ... Plans ” was created based on common inquiries the site’s team of third ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved ... procedure, and this procedure adds to SkyLex Advanced Surgical’s already comprehensive list ...
(Date:3/28/2017)... ... 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in people of all ... lot to offer to the discussion of dealing with excess skin oil. “Oily skin is ... home remedies that can help remove the oily shine while keeping the skin fresh and ...
(Date:3/27/2017)... Aurora, CO (PRWEB) , ... March 27, 2017 , ... ... Dr. Mark Braasch for leading sleep apnea treatment, with or without a referral. Sleep ... the condition, which can include daytime sleepiness, morning headaches and chronic snoring. , ...
(Date:3/27/2017)... ... March 27, 2017 , ... Biotechnology and ... and engagement over the household brands of Top-20 pharma by optimizing clinical trial ... partnering with the right outsourcing payments provider can provide the technology, infrastructure, and ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Elysium Health joins major pharmaceutical companies to ... Cambridge academic scientists through ... Institute today announces Elysium Health as a partner to the ... collaborative projects with academic researchers in Cambridge ... major research investment outside the U.S. for the ...
(Date:3/27/2017)... 27, 2017 Summary This ... Eli Lilly and its partnering interests and activities since 2010. ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ... The report will be delivered in PDF format ...
(Date:3/27/2017)... -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, announced ... efficacy studies. The company is harnessing the power of ... A, in an effort to find a better treatment ... 4 weeks of treatment in transgenic mice, the lead ... a full toxicology report of various organs. Cytotoxic T-cells ...
Breaking Medicine Technology: